Study of Zanubrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Clinical trial NCT05164770 · UNKNOWN

Trial details

NCT number: NCT05164770
Sponsor: Shandong Provincial Hospital
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

High Grade B-Cell Lymphoma, Not Otherwise Specified High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements Diffuse Large B Cell Lymphoma B-cell Non Hodgkin Lymphoma Mantle Cell Lymphoma

Start date: 2021-03-01
Primary completion: 2023-12-31
Enrollment: 160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.